Overview

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Status:
Withdrawn

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a Randomized, Open-Label Study of the Efficacy and Safety of Aralast NP Infusion Therapy with Antiviral Treatment and standard of care versus Antiviral Treatment and standard of care (control group) in Hospitalized Patients with Pneumonia and COVID-19 Infection.

Phase:

Phase 3

Details

Lead Sponsor:

Blessing Corporate Services, Inc

Collaborator:

Takeda Pharmaceuticals North America, Inc.

Treatments:

Alpha 1-Antitrypsin
Antiviral Agents
Protease Inhibitors
Remdesivir